Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NewAmsterdam Pharma Company N.V. Warrant (NAMSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: NAMSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 30.41% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.03 | 52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 |
52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2314.47% |
Management Effectiveness
Return on Assets (TTM) -18.15% | Return on Equity (TTM) -31.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 54899238 |
Shares Outstanding - | Shares Floating 54899238 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Warrant
Company Overview
History and Background
NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases with high unmet needs. The company was founded in 2019 and merged with Frazier Lifesciences Acquisition Corporation in 2022, becoming a publicly traded entity.
Core Business Areas
- Lipid Metabolism Research: Focuses on developing therapies to improve lipid profiles and reduce cardiovascular risk.
Leadership and Structure
The leadership team comprises experienced executives in pharmaceutical development and commercialization. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Obicetrapib: Obicetrapib is a cholesterol ester transfer protein (CETP) inhibitor being developed for lowering LDL-C and reducing cardiovascular events. Market share data is not currently available due to its developmental stage. Competitors include statins, PCSK9 inhibitors, and other emerging therapies for lipid management. The number of users and revenue generated cannot be projected until the drug is approved and commercialized.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on cardio-metabolic diseases is characterized by high unmet needs and significant market potential. The growing prevalence of cardiovascular disease drives demand for novel therapies.
Positioning
NewAmsterdam Pharma is positioned as a developer of innovative therapies targeting key drivers of cardiovascular risk, particularly lipid metabolism. They are trying to position themselves to be a front runner in the reduction of high cholesterol and the risks associated with it.
Total Addressable Market (TAM)
The total addressable market for lipid-lowering therapies is estimated to be in the billions of dollars. NewAmsterdam Pharma is positioning itself to capture a significant share of this market with Obicetrapib if it's successful.
Upturn SWOT Analysis
Strengths
- Novel CETP inhibitor mechanism
- Experienced management team
- Strong clinical trial data (early stage)
- Focus on high unmet needs
Weaknesses
- Dependence on a single product candidate (Obicetrapib)
- Clinical trial risks and regulatory hurdles
- Limited commercial infrastructure
- Cash Burn Rate
Opportunities
- Successful clinical trial outcomes leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into other cardio-metabolic indications
- Growing market for lipid-lowering therapies
Threats
- Competition from established therapies and emerging competitors
- Unfavorable clinical trial results
- Regulatory setbacks
- Pricing pressures
Competitors and Market Share
Key Competitors
- AMGN
- MRK
- REGN
Competitive Landscape
NewAmsterdam Pharma faces competition from established pharmaceutical companies with existing lipid-lowering therapies. Its competitive advantage lies in its novel CETP inhibitor mechanism, which could offer improved efficacy and tolerability compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Not applicable as the company is pre-revenue.
Future Projections: Future growth depends on the successful development and commercialization of Obicetrapib. Analyst estimates vary depending on the perceived likelihood of success. The stock price will likely fluctuate according to Phase 3 trials.
Recent Initiatives: Focus on advancing Obicetrapib through clinical trials and preparing for potential regulatory submissions.
Summary
NewAmsterdam Pharma is a clinical-stage company with potential in the cardio-metabolic space, hinging heavily on the success of Obicetrapib. Positive clinical trial results could lead to significant market opportunities. The company faces risks associated with drug development, competition, and regulatory hurdles. Further investment will be highly dependent on upcoming milestones.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 77 | |
Full time employees 77 | |||
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.